Mezzasalma Advisors LLC Sells 1,774 Shares of Sanofi $SNY

Mezzasalma Advisors LLC cut its stake in Sanofi (NASDAQ:SNY) by 14.3% during the second quarter, HoldingsChannel reports. The firm owned 10,591 shares of the company’s stock after selling 1,774 shares during the period. Mezzasalma Advisors LLC’s holdings in Sanofi were worth $512,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD grew its stake in Sanofi by 1.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 11,036,878 shares of the company’s stock worth $612,106,000 after acquiring an additional 193,196 shares in the last quarter. Federated Hermes Inc. boosted its holdings in shares of Sanofi by 58.5% in the first quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company’s stock valued at $218,933,000 after purchasing an additional 1,456,269 shares during the period. Envestnet Asset Management Inc. grew its stake in Sanofi by 6.9% in the first quarter. Envestnet Asset Management Inc. now owns 3,277,394 shares of the company’s stock worth $181,764,000 after purchasing an additional 211,641 shares in the last quarter. Raymond James Financial Inc. grew its stake in Sanofi by 15.1% in the first quarter. Raymond James Financial Inc. now owns 3,244,027 shares of the company’s stock worth $179,914,000 after purchasing an additional 425,597 shares in the last quarter. Finally, Nuveen LLC purchased a new position in Sanofi during the 1st quarter worth $177,831,000. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on SNY. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 2nd. Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Barclays reissued an “overweight” rating on shares of Sanofi in a research report on Wednesday, July 2nd. Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. upgraded shares of Sanofi from a “neutral” rating to an “overweight” rating in a research note on Friday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $62.67.

Sanofi Stock Performance

Shares of Sanofi stock opened at $50.62 on Friday. The company has a market capitalization of $124.30 billion, a PE ratio of 12.17, a P/E/G ratio of 1.23 and a beta of 0.51. The company has a 50-day simple moving average of $48.49 and a two-hundred day simple moving average of $49.60. Sanofi has a one year low of $44.62 and a one year high of $60.12. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). The firm had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The firm’s quarterly revenue was down 7.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.73 earnings per share. Research analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.